Amyloid spatial extent with florbetapir-PET for early detection of preclinical Alzheimer’s disease
EXT is a robust, generalizable PET metric that detects Aβ before global positivity and early Aβ-related changes in tau and cognition, supporting its relevance for trial enrichment and early therapeutic monitoring in AD prevention trials.
Authors
- Rachel F. Buckley (ORCID: https://orcid.org/0000-0002-5356-5537)
- Emma G. Thibault (ORCID: https://orcid.org/0000-0002-7873-742X)
- Julie C․ Price
- Keith A. Johnson
- Brian C. Healy
- Bernard J. Hanseeuw
- Michael J. Properzi
- Michelle E. Farrell
- Heidi I.L. Jacobs
- J․Alex Becker
- Reisa A. Sperling
- Grace Del Carmen Montenegro
Institutions
- Brigham and Women's Hospital (US)
- Cliniques Universitaires Saint-Luc (BE)
- Harvard University (US)
- Massachusetts General Hospital (US)
Publication Details
- Journal
- The Journal of Prevention of Alzheimer s Disease
- Published
- 2026-03-13
- DOI
- https://doi.org/10.1016/j.tjpad.2026.100529
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00